

Resource Summary Report

Generated by [RRID](#) on Aug 4, 2026

BD Biosciences: LSRFortessa Cell Analyzer

RRID:SCR_018655

Type: Tool

Proper Citation

BD Biosciences: LSRFortessa Cell Analyzer (RRID:SCR_018655)

Resource Information

URL: <https://www.bdbiosciences.com/en-us/instruments/research-instruments/research-cell-analyzers/lrfortessa>

Proper Citation: BD Biosciences: LSRFortessa Cell Analyzer (RRID:SCR_018655)

Description: BD LSRFortessa system can be configured with up to 7 lasers, blue, red, violet, UV and yellow-green. The instrument can accommodate the detection of up to 18 colors simultaneously with defined set of optical filters that meet or exceed the majority of today's assay requirements. BD FACSDiva software controls the efficient setup, acquisition, and analysis of flow cytometry data from the BD LSRFortessa workstation. The software is common across BD FACS instrument families, including the BD FACSCanto cell analyzer and BD FACSAria cell sorter systems.

Synonyms: BD LSRFortessa

Resource Type: instrument resource

Keywords: Flow cytometer, BD flow cytometer, multicolor flow cytometry assay, cell analysis, cell analyzer, laser, detect colors simultaneously, instrument, equipment

Specification URL: https://raw.githubusercontent.com/SciCrunch/RRID-Instruments/main/PDF/SCR_018655.pdf

Resource Name: BD Biosciences: LSRFortessa Cell Analyzer

Resource ID: SCR_018655

Alternate IDs: SCR_01960, SCR_019601, SCR_019602, SCR_019600, Model_Number_LSRFortessa, SCR_019605

Record Creation Time: 20220129T080341+0000

Record Last Update: 20260804T043700+0000

Ratings and Alerts

No rating or validation information has been found for BD Biosciences: LSRFortessa Cell Analyzer.

No alerts have been found for BD Biosciences: LSRFortessa Cell Analyzer.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 56 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Maerz MD, et al. (2026) BCG vaccination induces antibacterial effector functions among V α 1/3 T cells that are associated with protection against tuberculosis. Cell reports. Medicine, 102536.

Bischoff ME, et al. (2025) Copper Drives Remodeling of Metabolic State and Progression of Clear Cell Renal Cell Carcinoma. Cancer discovery, 15(2), 401.

Boccardo S, et al. (2025) Dynamics of tissue repair regulatory T cells and damage in acute Trypanosoma cruzi infection. PLoS pathogens, 21(1), e1012906.

Ma T, et al. (2025) Pan-Cancer Analyses Refine the Single-Cell Portrait of Tumor-Infiltrating Dendritic Cells. Cancer research, 85(19), 3596.

Bleve A, et al. (2025) ROR γ Bridges Cancer-Driven Lipid Dysmetabolism and Myeloid Immunosuppression. Cancer discovery, 15(7), 1505.

Sanlorenzo M, et al. (2025) Systemic IFN-I combined with topical TLR7/8 agonists promotes distant tumor suppression by c-Jun-dependent IL-12 expression in dendritic cells. Nature cancer, 6(1), 175.

Shen F, et al. (2025) Human Kallikrein 2: A Novel Lineage-Specific Surface Target in Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(21), 4543.

Song Z, et al. (2025) CTG-Initiated Cryptic Peptide Translation Up- and Downstream of a Canonical ATG Start Codon Is Enhanced by TLR Stimulation and Induces Tumor Regression in Mice. Cancer immunology research, 13(8), 1246.

Goswami M, et al. (2025) Increased Peripheral T Stem Cell-like Memory Features in Patients with Advanced Solid Tumors Treated with Tumor-Targeting IL-12 Immunocytokine Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(19), 4159.

Mu H, et al. (2025) Methionine intervention induces PD-L1 expression to enhance the immune checkpoint therapy response in MTAP-deleted osteosarcoma. *Cell reports. Medicine*, 6(3), 101977.

Lüönd F, et al. (2025) DLBCL Cells Emerge after CD19 CAR T Cells with Cross-Antigen Resistance and a Gene Signature Predictive of Clinical CAR T-cell Response. *Blood cancer discovery*, 6(6), 580.

Liljeström V, et al. (2025) B Cell dysfunction in tumor-draining lymph nodes predicts relapse in oral squamous cell carcinoma. *Cancer immunology, immunotherapy : CII*, 74(12), 373.

Chen X, et al. (2025) Fluvastatin Promotes Treg Cell Production in Allogeneic Immune Reaction and Suppresses Inflammatory Response. *Immunity, inflammation and disease*, 13(2), e70165.

MacMillan AC, et al. (2025) PRPS activity tunes redox homeostasis in Myc-driven lymphoma. *Redox biology*, 84, 103649.

Luo Y, et al. (2025) Single-cell clonal lineage tracing identifies the transcriptional program controlling the cell fate decisions by neoantigen-specific CD8 + T cells. *bioRxiv : the preprint server for biology*.

van der Heide V, et al. (2025) Prolonged but finite antigen presentation promotes reversible defects of "helpless" memory CD8+ T cells. *Immunity*, 58(7), 1742.

Li W, et al. (2025) Kurarinone and Nor-kurarinone inhibit NLRP3 inflammasome activation and regulate macrophage polarization against ulcerative colitis. *International immunopharmacology*, 157, 114758.

Joag V, et al. (2025) Primate resident memory T cells activate humoral and stromal immunity. *Immunity*, 58(10), 2541.

Ren Y, et al. (2025) eEF2K promotes immune evasion in melanoma via Cyclin D1-mediated stabilization of PD-L1. *Journal of immunology (Baltimore, Md. : 1950)*.

Álvarez-Prado ÁF, et al. (2025) Cancer cell and microenvironmental rewiring by ADAR1 loss impairs glioblastoma tumor growth and extends survival. *Cell reports*, 44(9), 116151.